Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURATION-4: Exenatide Once Weekly vs Oral Monotherapies in Drug-Naive T2DM
NCT00676338Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2008
- Primary completion
- Jul 2010
- Modality
- Peptides
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by AstraZeneca. Primary endpoints: Change in HbA1c From Baseline at 26 weeks and Percentage of Patients Achieving HbA1c <=7% at 26 weeks. Started Nov 2008; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00676338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00676338.